(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 June 2004 (10.06.2004)

PCT

(10) International Publication Number
WO 2004/047756 A2

(51) International Patent Classification[7]: A61K

(21) International Application Number:
PCT/US2003/037592

(22) International Filing Date:
20 November 2003 (20.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/301,540 21 November 2002 (21.11.2002) US

(71) Applicant *(for all designated States except BB)*: **TEVA PHARMACEUTICAL INDUSTRIES, LTD.** [IL/IL]; 5 Basel Street, P.O. Box 3190, Petach-Tikva 49131 (IL).

(71) Applicant *(for BB only)*: **TEVA PHARMACEUTICAL USA, INC.** [US/US]; 1090 Horsham Road, North Wales, PA 19454 (US).

(72) Inventors: **STERLING, Jeffrey**; 1 Ha'havtacha St., Ramot 02, Jerusalem 97275 (IL). **HAYARDENY, Liat**; 37 Yehuda Hanasi St., Tel-Aviv 69391 (IL). **FLAB, Eliezer**; 17 Hanegba St., Givataim 53450 (IL). **HERZIG, Yaacov**; 7 Hashirion St., Raanana 43266 (IL). **LERNER, David**; 27/4 Yigal St., Ramot 02, Jerusalem 97241 (IL).

(74) Agent: **WHITE, John, P.**; Cooper & Dunahm LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States *(regional)*: ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/047756 A2

(54) Title: PROPARGYL-TRIFLUOROMETHOXY-AMINO-BENZOTHIAZOLE DERIVATIVES



(I)

(57) Abstract: The subject invention provides compounds having the structure (I): wherein R_1 is present or absent, and when present is H, C_1-C_6alkyl, C_1-C_6 alkynyl, - $(CH_2)_yS$ $(CH_2)_xCH_3$, C_1-C_6 aminoalkyl, C_1-C_6 hydroxyalkyl or $-(CH_2)_nC(=O)$ (C_6H_4) $(CH_2)R_2$; R_2 is H or C_1-C_4 alkyl; R_3 is H or C_1-C_4 alkyl; R_4 is present or absent, and when present is H, C_1-C_6 alkyl, C_1-C_6 alkynyl, - $(CH_2)_yS(CH_2)_xCH_3$, C_1-C_6 aminoalkyl, C_1-C_6 hydroxyalkyl or $-(CH_2)_nC(=O)(C_6H_4)(CH_2)R_2$; wherein n is an integer from 1-6; wherein x is 0 or an integer from 1-5 and y is an integer from 1-5, such that x+y<6; at least one of R_1 or R_4 is present; the dashed line represents a bond between one of the nitrogen atoms and the intervening carbon atom; and any compound is charged when both $R_1$and R_4 are present, or any specific enantiomer thereof or any pharmaceutically acceptable salt thereof, and a method for treating a neurologic disorder or multiple sclerosis by administering a therapeutically effective amount any of the compounds..